The Hospital Gregorio Marañón, a world-renowned leader in cardiology, has launched a new prospective clinical trial to tackle one of the toughest challenges in electrophysiology: the effective treatment of long-standing persistent Atrial Fibrillation (AF).
The study, titled “Multitarget Pulse Field Ablation Guided by Endocardial and Non-invasive Atrial Driver Mapping (PFA+ADM) Pilot Study,”, is led by the hospital’s expert cardiology team, will investigate an innovative treatment strategy developed in collaboration with Corify Care, whose CE-marked ACORYS System is a central component of the study.
This foundational study is a key component of Corify Care’s comprehensive evidence-generation strategy. The insights gathered will be instrumental in refining the trial design for the company’s upcoming large-scale, international, multicenter study, CURE-AF.
The innovative strategy being investigated combines Corify’s real-time, global mapping platform with high-resolution endocardial mapping and Pulse Field Ablation (PFA). The aim is to use Corify’s global map to guide the precise, high-density mapping and subsequent PFA delivery, creating a “hybrid” mapping approach. This approach enables the prompt identification of newly emerging atrial drivers during the procedure and guides the multi-electrode catheter to areas of interest.
To ensure a robust and objective assessment of long-term outcomes, every patient enrolled in the trial will be monitored post-procedure with an implantable loop recorder (ILR). This commitment to high-quality, long-term evidence is central to the collaboration.
Corify Care is proud to partner with the team at Hospital Gregorio Marañón on this pioneering work, which is a cornerstone of our mission to build a new, data-driven standard of care in arrhythmia management.
-The Corify Care team
